|Bid||141.00 x 100|
|Ask||161.78 x 100|
|Day's range||149.31 - 152.93|
|52-week range||117.16 - 163.75|
|PE ratio (TTM)||24.67|
|Earnings date||26 Feb 2018 - 2 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||179.48|
Shares of Concert Pharmaceuticals (CNCE) nosedive after the Patent Trial and Appeal Board decided not to grant a Post Grant Review petition in patent '335 dispute with Incyte.
In 3Q17, Jazz Pharmaceuticals’ (JAZZ) Erwinaze generated revenue of $49 million, which reflected a rise of ~14% on a year-over-year (or YoY) basis.
In 3Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenue of $303.9 million, which reflected a rise of ~6% on a YoY (year-over-year) basis.
In 3Q17, Jazz Pharmaceuticals generated revenue of $411.9 million, which reflected a ~10% rise on a year-over-year basis and a 4% rise on a quarter-over-quarter basis.
In December 2017, Jazz Pharmaceuticals (JAZZ) submitted a New Drug Application (or NDA) to the FDA for the approval of JZP-110.
Jazz submits a new drug application to the FDA for JZP-110 (solriamfetol) for treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.
Drugmakers are using a variety of strategies to extend the exclusivity period of their wares, keeping less expensive alternatives away from patients.
SAN DIEGO, Dec. 04, 2017-- Vital Therapies, Inc., a biotherapeutic company developing ELAD ®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced the appointment ...
A medical charity that received hundreds of millions of dollars from pharmaceutical companies lost a crucial stamp of approval from the U.S. government, after allowing its donors improper influence over ...
Jazz Pharmaceuticals (JAZZ) earnings beat estimates while revenues miss the same in Q3. The company also cuts its guidance due to lower-than-expected sales from Xyrem.
Jazz Pharmaceuticals' (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q3, thanks to label expansion efforts. Also, other products look promising to lead to an earnings beat.
Genocea Biosciences (GNCA) was a big mover last session, as the company saw its shares rise almost 25% on the day amid huge volumes.